Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions

• Prif Awduron: Saima Subhani (Awdur), Viera Lukacova (Awdur), Chaejin Kim (Awdur), Leyanis Rodriguez-Vera (Awdur), Paula Muniz (Awdur), Monica Rodriguez (Awdur), Rodrigo Cristofoletti (Awdur), Sandra Van Os (Awdur), Elena Suarez (Awdur), Stephan Schmidt (Awdur), Valvanera Vozmediano (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2023-02-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega^®) for the once-daily treatment of schizophrenia. This osmotic-controlled release oral delivery system (OROS) offers advantages, such as the prevention of plasma concentration fluctuation...